RT Journal Article
SR Electronic
T1 Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement over-activation
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.03.29.20041962
DO 10.1101/2020.03.29.20041962
A1 Gao, Ting
A1 Hu, Mingdong
A1 Zhang, Xiaopeng
A1 Li, Hongzhen
A1 Zhu, Lin
A1 Liu, Hainan
A1 Dong, Qincai
A1 Zhang, Zhang
A1 Wang, Zhongyi
A1 Hu, Yong
A1 Fu, Yangbo
A1 Jin, Yanwen
A1 Li, Kaitong
A1 Zhao, Songtao
A1 Xiao, Yongjiu
A1 Luo, Shuping
A1 Li, Lufeng
A1 Zhao, Lingfang
A1 Liu, Junli
A1 Zhao, Huailong
A1 Liu, Yue
A1 Yang, Weihong
A1 Peng, Jing
A1 Chen, Xiaoyu
A1 Li, Ping
A1 Liu, Yaoning
A1 Xie, Yonghong
A1 Song, Jibo
A1 Zhang, Lu
A1 Ma, Qingjun
A1 Bian, Xiuwu
A1 Chen, Wei
A1 Liu, Xuan
A1 Mao, Qing
A1 Cao, Cheng
YR 2020
UL http://medrxiv.org/content/early/2020/03/30/2020.03.29.20041962.abstract
AB An excessive immune response contributes to SARS-CoV, MERS-CoV and SARS-CoV-2 pathogenesis and lethality, but the mechanism remains unclear. In this study, the N proteins of SARS-CoV, MERS-CoV and SARS-CoV-2 were found to bind to MASP-2, the key serine protease in the lectin pathway of complement activation, resulting in aberrant complement activation and aggravated inflammatory lung injury. Either blocking the N protein:MASP-2 interaction or suppressing complement activation can significantly alleviate N protein-induced complement hyper-activation and lung injury in vitro and in vivo. Complement hyper-activation was also observed in COVID-19 patients, and a promising suppressive effect was observed when the deteriorating patients were treated with anti-C5a monoclonal antibody. Complement suppression may represent a common therapeutic approach for pneumonia induced by these highly pathogenic coronaviruses.One Sentence Summary The lectin pathway of complement activation is a promising target for the treatment of highly pathogenic coronavirus induced pneumonia.Competing Interest StatementThe authors have declared no competing interest.Clinical Trial2020L0003Funding StatementNational Science and Technology Major Projects (2018ZX09711003-005-005 and 2018ZX09201017-007), National Basic Research Program of China (2012CB518902)Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is always available for researches interested in this study.